NCT07020832撤回3 期
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 入组人数
- 320
- 试验地点
- 1
- 主要终点
- Time to freedom from dialysis through Day 90
研究概览
简要总结
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged at least 18 years
- •Have end-stage kidney disease and be on the waiting list for a kidney transplant from a deceased donor.
- •Be on dialysis at the time of your transplant and produce very little urine (less than 200 mL per day equivalent to ≤1 cup). You must have been on dialysis for at least 3 months.
- •Be receiving your first or second kidney transplant from a deceased donor. If this is your second transplant:
- •It cannot be due to a serious infection or a serious blood clot in your previous transplant.
- •Your calculated Panel Reactive Antibody (CPRA) level must be below 50%.
- •Be getting a donor kidney that meets the study's specific requirements.
- •Be at low to medium risk of transplant rejection, and be scheduled to receive:
- •A medication called ATG as part of your transplant procedure.
- •Steroids (corticosteroids) as part of your treatment at the time of screening.
- •A medication called tacrolimus (or a similar drug) after your transplant, according to usual medical practice.
- •Have received certain vaccines before starting the study treatment, specifically:
- •Pneumococcal (S. pneumoniae)
- •Meningococcal (N. meningitidis types A, C, W, Y, and B)
- •Haemophilus influenzae type B
- •If you haven't had these vaccines, you may still qualify to be part of the study, provided your doctor plans to administer preventive antibiotics until vaccination can be given per protocol, and with notification to the sponsor.
排除标准
- •Have taken part in another medical research study or used an experimental drug, treatment, or device in the past 30 days (or longer, depending on the drug).
- •Have recently used certain medications that affect the immune system, such as rituximab, belimumab, or other approved complement-blocking drugs.
- •Weigh less than 20kg or more than 120kg at screening.
- •Have or had recently had any of the following infections:
- •Hepatitis B or Hepatitis C (unless treated and no longer active).
- •HIV (human immunodeficiency virus) at any time.
- •Have had cancer in the past 5 years, unless it was:
- •A small, treated skin cancer (like basal or squamous cell), or
- •A very small kidney cancer that was found early and treated.
- •Have received any other organ transplant (except for one previous kidney transplant), or are scheduled for a transplant involving more than one organ.
研究组 & 干预措施
Pegceptacoplan
Active Comparator
Administration as a 20mL IV infusion initially, then as a subcutaneous infusion
干预措施: Pegcetacoplan (Drug)
Placebo
Placebo Comparator
Administration as a 20mL IV infusion initially, then as a subcutaneous infusion
干预措施: Placebo (Other)
结局指标
主要结局
Time to freedom from dialysis through Day 90
时间窗: Duration of dialysis through day 90
To assess the efficacy of pegcetacoplan compared with that of placebo in participants at high risk of DGF following donor kidney allograft transplant surgery
次要结局
- eGFR at Week 52(52 weeks following surgery)
- Proportion of participants with DGF (defined as the need for dialysis in the 7 days posttransplant)(7 days following surgery)
- eGFR at Day 90(90 days following surgery)
- Time to achievement of ≥1200 mL of urine output in a 24-hour period through Day 14(14 days following surgery)
- Biopsy-proven rejection-free kidney allograft survival by Week 52(52 weeks following surgery)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)Cold Agglutinin DiseaseNCT05096403Swedish Orphan Biovitrum57
已完成
3 期
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled AsthmaUncontrolled AsthmaNCT02161757AstraZeneca1,207
已完成
3 期
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled AsthmaUncontrolled AsthmaNCT02194699AstraZeneca856
已完成
3 期
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)Idiopathic Parkinson DiseaseIdiopathic Parkinson's DiseaseParkinson DiseaseNCT01227265Merck Sharp & Dohme LLC476
终止
3 期
Magnesium Sulfate in the Prevention of Post-ERCP Pancreatitis.Post-ERCP PancreatitisNCT03749590University Medicine Greifswald327